- Ukwelashwa
- Ubufakazi
- I-Neuroblastoma
- Isimila Esiqinile
- Ubufakazi
- I-TILS
- Ukwelashwa Kwamaseli e-NK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-Non-Hodgkin Lymphoma (NHL)
- I-Multiple Myeloma (MM)
- I-Diffuse Large B-cell Lymphom
- I-B-lymphocytic Leukemia
- I-Myeloma
I-CAR-T ye-Acute B-cell Lymphoblastic Leukemia (B-ALL)
Ukubuka konke
I-B-ALL (Acute B-cell Lymphoblastic Leukemia) iwuhlobo olunamandla lwe-leukemia, oluthinta kakhulu izingane kanye nabantu abadala abasebasha. Naphezu kwentuthuko ekusetshenzisweni kwamakhemikhali endabuko, iziguli eziningi zithola ukuphinda zibuyele esimweni sazo noma ukumelana nokwelashwa. Ukwelashwa kwe-CAR-T (Chimeric Antigen Receptor T-cell) kumelela ukwelashwa okumangalisayo kwe-immunotherapy okuye kwabonisa impumelelo emangalisayo ekwelapheni i-B-ALL ephinde yabuyela esimweni sayo noma engaphikisi, okunikeza ithemba ezigulini ezazinezinketho zokwelapha ezilinganiselwe ngaphambilini.
Kuyini Ukwelashwa Kwe-CAR-T?
Ukwelashwa kwe-CAR-T kuyindlela yokwelapha ethuthukisiwe, eyenzelwe wena ehilela ukuguqula ama-T-cell esiguli ukuze aqaphele futhi ahlasele amaseli omdlavuza. Kuma-B-ALL, amaseli e-CAR-T aklanywe ukuze ahlasele i-CD19 antigen, iphrotheni evame ukutholakala ebusweni bamaseli e-B-cell leukemia. Uma esebuyiselwe emzimbeni wesiguli, la maseli e-T aklanywe ngendlela ethuthukisiwe afuna futhi abhubhise amaseli e-leukemia, okungenzeka ukuthi aholele ekuphumuleni okuhlala isikhathi eside.
Izinzuzo Eziyinhloko Zokwelashwa Kwe-CAR-T Kwe-B-ALL
- Ukusebenza Okuphezulu: Ukwelashwa kwe-CAR-T kubonise impumelelo emangalisayo ekwelapheni i-B-ALL ephinde yabuya noma engaphili kahle, okunikeza izinga eliphezulu lokuphulukiswa ezigulini ezingazange zisabele ekwelashweni kwendabuko.
- Isenzo Esiqondiwe: Ngokugxila ku-antigen ye-CD19, ukwelashwa kwe-CAR-T kuhlasela futhi kubhubhise ngqo amaseli e-B-ALL, kunciphisa umonakalo ezicutshini ezinempilo.
- Ukwelashwa Okuqondene Nakho: Njengoba amaseli e-CAR-T etholakala ohlelweni lokuzivikela lomzimba lwesiguli, ukwelashwa kwenziwa ngokwezifiso kakhulu, kwandisa ukusebenza kwayo futhi kunciphisa ingozi yokwenqatshwa.
- Ukuxolelwa Okuhlala Isikhathi EsideEzimweni eziningi, ukwelashwa kwe-CAR-T kuholele ekuphumuleni okuhlala isikhathi eside, okunikeza iziguli ithuba lokusinda isikhathi eside ngokuphindaphinda okuncane.
Inqubo Yokwelapha
- Ukuqoqwa kwamaseli e-TIsinyathelo sokuqala sihilela ukuqoqa amaseli e-T egazini lesiguli ngenqubo ebizwa ngokuthi i-leukapheresis.
- Amaseli e-T obunjiniyela: Amaseli e-T aqoqiwe aguqulwa ngokwezakhi zofuzo elabhorethri ukuze aveze i-chimeric antigen receptor (CAR) ethize ku-CD19, okuthuthukisa ikhono lawo lokuhlasela amaseli e-B-ALL.
- Ukufakwa Kwamaseli E-CAR-TNgemva kwesikhathi esifushane sokwanda kwamaseli, amaseli e-CAR-T aklanywe ngendlela ethuthukisiwe aphinde afakwe emzimbeni wesiguli ngokufakwa kwe-intravenous (IV).
- Ukuqapha Nokubuyisela Esimeni: Ngemva kokumnika, iziguli ziqashwe ngokucophelela ukuze zithole imiphumela emibi engaba khona njenge-cytokine release syndrome (CRS) kanye nobuthi be-neurotoxicity. Lokhu kusabela ngokuvamile kuyalawuleka, futhi iningi leziguli liyalulama ngokungenelela okufanele.
Kungani Kufanele Ukhethe Ukwelashwa Kwe-CAR-T Kwe-BIOOCUS Kwe-B-ALL?
- Ubuchwepheshe Besimanje: I-BIOOCUS isebenzisa ubuchwepheshe obusezingeni eliphezulu ukuqinisekisa ukukhiqizwa kwamaseli e-CAR-T okuhle kakhulu kanye nemiphumela yeziguli.
- Ithimba Lezokwelapha Elingochwepheshe: Ithimba lethu lochwepheshe be-hematology kanye ne-immunotherapy lizinikele ekuhlinzekeni ukunakekelwa komuntu siqu kanye nokukhulisa impumelelo yokwelashwa ngakunye.
- Okuhlangenwe Nakho Kwamazwe Ngamazwe: Sinikeza ukwelashwa kwe-CAR-T ezigulini ezivela emhlabeni wonke, ngomlando wokwelashwa okuphumelelayo kanye nokuphulukiswa kwesikhathi eside kweziguli ze-B-ALL.
- Ukunakekelwa OkupheleleKusukela ekubonisaneni kokuqala kuya ekuqapheni okulandelayo, i-BIOOCUS inikeza ukunakekelwa okuphelele, okuqinisekisa ukuthi iziguli zithola ukwelashwa okungcono kakhulu kuzo zonke izigaba.
Ubufakazi Bezokwelapha kanye Namazinga Empumelelo
Izivivinyo zemitholampilo zakamuva kanye nedatha yangempela ikhombisile ukuthi ukwelashwa kwe-CAR-T kwe-B-ALL kunikeza imiphumela emihle kakhulu, ikakhulukazi ezigulini eziphinde zabuyela emuva noma ezingamelani nokwelashwa kwendabuko. Ukwelashwa kuye kwabonisa njalo amazinga aphezulu okuphulukiswa, lapho iziguli eziningi zithola ukuphulukiswa okuphelele futhi zilondoloza ukusinda isikhathi eside.
Kwa-BIOOCUS, selaphe ngempumelelo iziguli eziningi nge-B-ALL sisebenzisa ukwelashwa kwe-CAR-T, futhi imiphumela ibe mihle kakhulu. Ukuze uthole ukuqonda okujulile ngezindaba zempumelelo nemiphumela yangempela, sicela uhlole izifundo ezilandelayo zeziguli:
- Indaba Yesiguli: I-B-ALL Eyingozi Kakhulu, Ukufakelwa Umongo Wethambo Ezinyangeni Eziyi-9—Eminyakeni Emibili Kamuva, Isiqalo Esinempilo
- Kusukela Ekuhlulekeni Kokuqala Kokufakelwa Kwezitho Zokufakelwa Kuya Ekululameni Okugcwele: Uhambo Lwesiguli Ngokufakelwa Kwezitho Zokufakelwa Okuthuthukisiwe KukaLu Daopei
- Ulwazi Lomkhiqizo kanye Nezifundo Ze-Acute Lymphoblastic Leukemia (B-ALL)
La macala aqokomisa amandla okuguqula ukwelashwa kwe-CAR-T kweziguli ze-B-ALL, engabonisi nje kuphela ukusebenza kahle kokwelashwa kodwa futhi nekhono lakho lokunikeza iziguli ithuba lesibili lokuphila.
Idatha Yezokwelapha
Izinkomba ze-CD19+20CAR-T:Iziguli ezine-B-cell non-Hodgkin's lymphoma
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 71.95% (59/82) | 25.6（21/82） | 97.55（80/82） | 12.19% (10/82) | 0 |
Izinkomba ze-CD19+22CAR-T:Ukwelashwa kweziguli ezine-CD19 eziphinde zabuyela emuva futhi ezingasabeli kahle i-B-lymphocytic leukemia
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 92.1%（35/38） | 7.9%（3/38） | 100% (38/38) | 15.79% (6/38) | 0 |
Izinkomba ze-BCMACAR-T:Ukwelashwa kwe-myeloma eminingi ephinde yabuya futhi engaphikisi
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 72.41% (21/29) | 27.59%（8/29） | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.